These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 7699618)
21. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Anderson JJ; Wells G; Verhoeven AC; Felson DT Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696 [TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA; Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444 [TBL] [Abstract][Full Text] [Related]
23. Measurement of gold treatment effect in clinical practice: evidence for effectiveness of intramuscular gold therapy. Wolfe F; Hawley DJ; Cathey MA J Rheumatol; 1993 May; 20(5):797-802. PubMed ID: 8336305 [TBL] [Abstract][Full Text] [Related]
24. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Sultan N; Pope JE; Clements PJ; Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295 [TBL] [Abstract][Full Text] [Related]
25. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645 [TBL] [Abstract][Full Text] [Related]
26. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Verstappen SM; van Albada-Kuipers GA; Bijlsma JW; Blaauw AA; Schenk Y; Haanen HC; Jacobs JW; Ann Rheum Dis; 2005 Jan; 64(1):38-43. PubMed ID: 15130899 [TBL] [Abstract][Full Text] [Related]
27. The responsiveness of generic health status measures as assessed in patients with rheumatoid arthritis receiving infliximab. Russell AS; Conner-Spady B; Mintz A; Maksymowych WP J Rheumatol; 2003 May; 30(5):941-7. PubMed ID: 12734886 [TBL] [Abstract][Full Text] [Related]
28. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. OMERACT/ILAR Task Force on Generic Quality of Life. Life Outcome Measures in Rheumatology. International League of Associations for Rheumatology. Wells G; Boers M; Shea B; Tugwell P; Westhovens R; Saurez-Almazor M; Buchbinder R J Rheumatol; 1999 Jan; 26(1):217-21. PubMed ID: 9918267 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058 [TBL] [Abstract][Full Text] [Related]
30. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. Stone M; Fortin PR; Pacheco-Tena C; Inman RD J Rheumatol; 2003 Oct; 30(10):2112-22. PubMed ID: 14528503 [TBL] [Abstract][Full Text] [Related]
31. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Watson KD; Silman AJ; Symmons DP; Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [TBL] [Abstract][Full Text] [Related]
32. Responsiveness of the International Classification of Functioning, Disability and Health (ICF) Core Set for rheumatoid arthritis. Uhlig T; Moe R; Reinsberg S; Kvien TK; Cieza A; Stucki G Ann Rheum Dis; 2009 Jun; 68(6):879-84. PubMed ID: 18625628 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503 [TBL] [Abstract][Full Text] [Related]
34. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396 [TBL] [Abstract][Full Text] [Related]
35. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172 [TBL] [Abstract][Full Text] [Related]
36. A reappraisal of HAQ disability in rheumatoid arthritis. Wolfe F Arthritis Rheum; 2000 Dec; 43(12):2751-61. PubMed ID: 11145033 [TBL] [Abstract][Full Text] [Related]
37. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102 [TBL] [Abstract][Full Text] [Related]
38. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis--a cross sectional study. Tett SE; Day RO; Cutler DJ J Rheumatol; 1993 Nov; 20(11):1874-9. PubMed ID: 8308772 [TBL] [Abstract][Full Text] [Related]
39. Combination therapy in rheumatoid arthritis--no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. Porter DR; Capell HA; Hunter J J Rheumatol; 1993 Apr; 20(4):645-9. PubMed ID: 8496858 [TBL] [Abstract][Full Text] [Related]
40. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. Goldsmith CH; Boers M; Bombardier C; Tugwell P J Rheumatol; 1993 Mar; 20(3):561-5. PubMed ID: 8478874 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]